MARKET

AUPH

AUPH

Aurinia Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.56
-0.39
-2.45%
After Hours: 15.56 0 0.00% 16:41 07/02 EDT
OPEN
16.07
PREV CLOSE
15.95
HIGH
16.14
LOW
15.50
VOLUME
791.97K
TURNOVER
--
52 WEEK HIGH
21.93
52 WEEK LOW
3.520
MARKET CAP
1.75B
P/E (TTM)
-11.8997
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AUPH stock price target is 25.00 with a high estimate of 32.00 and a low estimate of 20.00.

EPS

AUPH News

More
Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Benzinga · 06/22 10:14
Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced it has completed enrollment for the Phase 2/3 AUDR
Business Wire · 06/22 10:05
Is Aurinia Pharmaceuticals Stock a Buy?
Motley Fool · 06/09 15:20
Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020
Business Wire · 06/09 11:05
Hedge Funds Keep Buying Aurinia Pharmaceuticals Inc (AUPH)
Insider Monkey · 06/08 08:00
Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress
Business Wire · 06/05 12:05
Aurinia Presents Aurora Pivotal Trial Subgroup Analysis At The Eular 2020 E-Congress
- All pre-specified subgroup analyses in the pivotal trial favored voclosporin over placebo - VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (“Aurinia” or
All pre-specified subgroup analyses in the pivotal trial favored voclosporin over placebo - VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (“Aurinia” or · 06/05 11:08
Biotech Stocks: Buy This, Not That
Motley Fool · 06/04 11:34

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About AUPH

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.
More

Webull offers kinds of Aurinia Pharmaceuticals Inc stock information, including NASDAQ:AUPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AUPH stock methods without spending real money on the virtual paper trading platform.